Antidepressants may be kicked off protected drug list
Six protected drug classes could be whittled down to three by 2016
Current Part D rules offer some flexibility in formularies, requiring at least two drugs in 148 categories, but the Centers for Medicare and Medicaid Services (CMS) does not dictate specifically which drugs.
However, drug plan sponsors currently must cover “all” or “substantially all” of the protected drug classes identified by CMS:
• anti-convulsants;
• antidepressants;
• anti-cancer;
• anti-psychotics;
• anti-retrovirals; and
• immunosuppressants for the treatment of transplant rejection.
A proposal from CMS would end the protected status for antidepressants and immunosuppresants in 2015, and possibly anti-psychotics in 2016. A recent House Energy and Commerce Committee meeting had both Democrats and Republicans pushing back against the proposal.
It’s not unusual for a patient on an antidepressant to switch drugs within the class to optimize outcomes and reduce side effects, and advocates want patients to have enough choices on formulary to make the necessary switches. Coverage often correlates with treatment adherence for seniors on antidepressants.
Federal officials say ending the protected status of the three drug classes would reduce costs and foster competition. It’s not that CMS is randomly picking classes, rather, CMS proposes to use criteria from the Affordable Care Act that translate to limiting the protected classes to those for which access to all drugs in a class-for a typical patient who needs those drugs-is required within seven days’ time.
Public comment is accepted until March 7, 2014.
David Calabrese of OptumRx Talks New Role, Market Insulin Prices and Other Topics 'On His Mind'
April 13th 2023In this month’s episode of the "What's On Your Mind podcast," Peter Wehrwein, managing editor of MHE connects with the now Chief Clinical Officer of OptumRx Integrated Pharmacies, David Calabrese. In this conversation, David touches on his transition in January as OptumRx’s former chief pharmacy officer and market president of health plans and PBMs to his new role as Chief Clinical Officer where he now focuses more on things such as specialty pharmacy to home delivery — with an overall goal of creating whole-patient care. Throughout the conversation, Calabrese also touched on the market’s hot topic of insulin prices and behavioral health services within the OptumRx community, among other topics.
Listen
Upended: Can PBM Transparency Succeed?
March 6th 2024Simmering tensions in the pharmacy benefit management (PBM) industry have turned into fault lines. The PBMs challenging the "big three" have formed a trade association. Purchaser coalitions want change. The head of the industry's trade group says inherent marketplace friction has spilled over into political friction.
Read More
Briana Contreras, editor of Managed Healthcare Executive, spoke with Nancy Lurker, CEO and president of EyePoint Pharmaceuticals. Nancy shared a bit about EyePoint and how the organization’s innovative therapies are addressing patient needs through eye care, and most importantly, she addressed C-Suite positions like the CEO role. Nancy shared advice for those seeking to reach the CEO level, especially toward women in healthcare and other roles, and what it takes to run a biopharma company.
Listen
The deliberate disconnection of Change Healthcare to ring fence a cyberattack entered its seventh day today. Prescribers are finding ways to get pharmacy claims processed, and UnitedHealth Group says disruption to the dispensing of prescriptions has been minimal. But independent pharmacies want more information and protection from financial consequences from pharmacy benefit managers.
Read More
